Sep 30, 2026 8:05 am EDT Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration
Aug 12, 2026 4:05 pm EDT Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress